Clinical Laserthermia Systems

About:

Clinical Laserthermia Systems develops and markets the TRANBERG®|Thermal Therapy System for heat-induced immunotherapy.

Top Investors: EASME - EU Executive Agency for SMEs

Description:

Clinical Laserthermia Systems (CLS) develops and markets the TRANBERG®|Thermal Therapy System, as well as disposable materials and methods, for heat-induced immunotherapy enabling safe and gentle treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for CLS’ own immunostimulating therapy, imILT®. The company is headquartered in Lund, Sweden, with subsidiaries in Berlin, Germany and in Boston, USA. CLS is listed on Nasdaq First North under the stock symbol CLS B.

Total Funding Amount:

2.14M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Lund, Skane Lan, Sweden

Founded Date:

2006-01-01

Contact Email:

info(AT)clinicallaser.se

Founders:

Karl Goran Tranberg, Lars-Erik T. Eriksson, Par H Henriksson

Number of Employees:

11-50

Last Funding Date:

2016-08-01

IPO Status:

Public

Industries: